Associate Professor, Medicine, Boston University School of Medicine
Oncology
Dr. Omar Eton, MD
|
|
Give Review
Omar Eton, MD works in the field of Oncology. He studied medicine at NYU School of Medicine. He has 8 awards "Patients Choice Awards", "Top Doctor in Massachusetts", "Compassionate Doctor Award - National", "Consultant to the Surgeon General for Hemaology/Oncology", "Recognition of academic achievement of the highest distinction (non-financial award)", "U.S. Meritorious Service Medal", "Fellow" and "Clinical Oncology Fellowship". Omar Eton is also a published physician. He has 20 publication published. The most recent publication is: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Omar Eton is registered with Medicare.
Publications
- Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic Melanoma.
- Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal Melanoma.
- Sequential biochemotherapy versus chemotherapy for metastatic Melanoma: results from a phase III randomized trial.
- Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic Melanoma.
- Phase II evaluation of temozolomide in metastatic choroidal Melanoma.
- Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.
- Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of Melanoma cells but does not affect tumorigenicity in vivo.
- Biochemotherapy in patients with metastatic anoRectal mucosal melanoma.
- Phase II evaluation of paclitaxel by short intravenous infusion in metastatic Melanoma.
- Pilot study of high-dose, concurrent biochemotherapy for advanced Melanoma.
- Chemotherapy, cytokines, and biochemotherapy for Melanoma.
- Multicenter Phase II trial of high-dose imatinib mesylate in metastatic Melanoma: significant toxicity with no clinical efficacy.
- Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
- Changes in pERK1/2 and pAKT expression in Melanoma lesions after imatinib treatment.
- A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for Melanoma recurrence.
- A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung Cancer.
- Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic Melanoma.
- Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid Tumors.
- Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid Tumors: safety, pharmacokinetics, and pharmacodynamics.
Schools
New York University School Of Medicine
Parkland Meml Hospital University Tex Sw
Parkland Health and Hospital System
Memorial SloanKettering Cancer Center
Harvard Coll
Procedures Preformed
- Cancer Treatment
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Patients’ Choice Awards
- Top Doctor in Massachusetts
- Compassionate Doctor Award - National
- Consultant to the Surgeon General for Hemaology/Oncology
- Recognition of academic achievement of the highest distinction (non-financial award)
- U.S. Meritorious Service Medal
- Fellow
- Clinical Oncology Fellowship
Education
-
Memorial Sloan-Kettering Cancer Center -
NYU School of Medicine -
Harvard College
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1275736050 | |
| NPPES Provider LastName | ETON | |
| NPPES Provider FirstName | OMAR | |
| NPPES Provider ZIPCode | 021182905 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 169.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 37.0 | |
| Percent Opioid Claims | 21.89 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1275736050 |
| Last Name Of The Provider | ETON |
| First Name Of The Provider | OMAR |
| View All |
Similar Doctors
|
Dr. Panagiotis Konstantinopoulos, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rachel Buchsbaum, MD
This Doctor is OpenDoctor Recommended.
|